RCPath Webinar – Defining Adverse Effects in Non-clinical Toxicity Studies
This webinar will focus on the identification and characterisation of hazards, identified for drugs in development, in preparation for ‘first in man’ clinical trials. Toxicity studies, of varying durations, in laboratory animal species, are required by government, drug regulatory, agencies worldwide, and are intended to characterise the hazards inherent in dosing small molecule chemical entities to biological systems, the dose response for these hazards, and the ‘dose limiting’ toxicity that could potentially occur when the same drugs are given to humans in clinical trials. Currently, only these animal studies can be used to assess the potential safety of dosing the same entity into humans. The results of these safety studies, together with other data, including the efficacy of the drug for the proposed therapeutic disease, are presented in a prescribed way, for review by regulatory agencies and the results will provide the basis for a decision as to the applicability of the drug for further development, including initial tolerability studies in humans.
Speakers: Professor John R Foster and Dr Jan Klapwijk
This meeting will be held via Zoom on 17th April 2024, starting at 12.30 pm and last approximately 1 hour.
CPD: This meeting is worth 1 CPD point (self credited).
Date(s) - 17/04/2024
12:30 pm - 1:30 pm